The trends reported by Broderick et al. have continued. During 2006–2014, the incidence of meningococcal disease caused by vaccine-covered serogroups among US military recipients of MCV-4 fell to 0.146 per 100,000 person-years, whereas MPVS-4–related incidence did not change (M.P. Broderick, pers. comm.). Furthermore, through July 2016, the US military has not seen a case from a covered serogroup since 2011 among recipients of MCV-4. Even with these additional data, however, the difference between MCV-4 and MPSV-4 does not achieve statistical significance (M.P. Broderick, pers. comm.).

The author is an employee of a company that manufactures both conjugate and polysaccharide meningococcal vaccines.

Reference

Address for correspondence: Michael Decker, Sanofi Pasteur, Medical Affairs, 1 Discovery Dr, Swiftwater, PA 18370, USA; email: eid@deckerfamily.org